Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report
In Case Reports in Pathology, 2007
... 8G7G3/1 clone, Cell Marque, Rocklin, CA, USA), cytokeratin 7 (OV-TL clone, Dako, Carpinteria, CA, USA), and cytokeratin 20 (K520.8
A case of primary small cell carcinoma of the breastmore suppliers
In Pathology Research International, 2006
... 1 : 3000), high molecular weight cytokeratin (CK; Dako, clone 34BE12, 1 : 150), CK8/18 (Novocastra, clone 5D3, 1 : 50), CK20 (Dako, clone Ks20.8, 1 : 100), CK7 ...
B cell-directed therapies in multiple sclerosis.
München, Germany. In Neurodegener Dis Manag, Feb 2016
Three therapeutic monoclonal antibodies targeting CD20-positive B cells (rituximab, ocrelizumab and ofatumumab) were investigated in MRI-based Phase II and Phase III trials in RRMS, providing consistent evidence for a disease-ameliorating effect of B cell depleting therapies in MS.
Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.
Stockholm, Sweden. In Apmis, Feb 2016
Slides were stained for estrogen, progesterone and androgen receptor, prolactin, PSA, prostein, PSMA, PSAP, CDX2, lysozyme, villin, monoclonal CEA, CK7, CK20, HMWCK, p63, p504s, c-Myc, EGFR, Ki-67, p16, p21, p27, p53, PTEN, ERG, and PAX-8.
Hypersensitivity reactions during treatment with biological agents.
Pisa, Italy. In Clin Exp Rheumatol, Feb 2016
UNASSIGNED: The recent development of biological agents, namely, anti-tumour necrosis factor alpha (TNF-α) agents (infliximab, adalimumab and etanercept), anti- CD20 monoclonal antibody (rituximab) and anti-interleukin 6 receptor (IL-6R) monoclonal antibody (tocilizumab), represents a major breakthrough for the treatment of immune-mediated disorders.
Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations.
İzmir, Turkey. In Rare Tumors, Jan 2016
The tumor cells were negative for CK7, CK20, CD3, CD20, LCA, CDX2, uroplakin, thyroid transcription factor 1, PSA and p63.
Effector B cells in autoimmune diseases.
More papers using
In Nihon Rinsho Meneki Gakkai Kaishi, 2014
Given risk/benefit considerations, a novel strategy to selectively target the function of effector B cells would be more preferable than the nonselective B-cell depletion achieved by anti-CD20 therapy in AID.
Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis
In Head and Neck Pathology, 2004
... (Novocastra, Newcastle, UK), PS-1 (CD3; Immunotech, Marseille, France), 4C7 (CD5; Novocastra), 56C6 (CD10; Novocastra), L26 (CD20; Dako A/S, Glostrup, Denmark), 1B12 ...